IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis
Uveitis, a group of heterogeneous diseases causing ocular inflammation, is a major contributor to vision loss globally. While systemic corticosteroids (CS) are the mainstay treatment, identifying CS-refractory patients remains a significant challenge. This study aimed to explore cytokine expression...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1584905/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850190077103177728 |
|---|---|
| author | Rodrigo A. Valenzuela Rodrigo A. Valenzuela Fabian Vega-Tapia Nathaly Elizalde Ivan Flores Felipe M. Rojas Felipe M. Rojas Felipe M. Rojas Felipe M. Rojas Annelise Goecke Loreto Cuitino Loreto Cuitino Cristhian A. Urzua Cristhian A. Urzua Cristhian A. Urzua |
| author_facet | Rodrigo A. Valenzuela Rodrigo A. Valenzuela Fabian Vega-Tapia Nathaly Elizalde Ivan Flores Felipe M. Rojas Felipe M. Rojas Felipe M. Rojas Felipe M. Rojas Annelise Goecke Loreto Cuitino Loreto Cuitino Cristhian A. Urzua Cristhian A. Urzua Cristhian A. Urzua |
| author_sort | Rodrigo A. Valenzuela |
| collection | DOAJ |
| description | Uveitis, a group of heterogeneous diseases causing ocular inflammation, is a major contributor to vision loss globally. While systemic corticosteroids (CS) are the mainstay treatment, identifying CS-refractory patients remains a significant challenge. This study aimed to explore cytokine expression and Glucocorticoid Receptor (GR) levels as biomarkers for the early detection of CS-refractory cases in non-infectious uveitis. We assayed blood samples from 19 patients with non-infectious uveitis, for the expression of IL-6, IL-17A, TNF-α, IL-10 and GRα. The cohort included 11 refractory and 8 sensitive patients, categorized based on their clinical response to corticosteroids (prednisone 1 mg/kg/day). Blood draws were conducted at three time points (at baseline, day 7- and day 14 after CS initiation), and peripheral blood mononuclear cells (PBMCs) were isolated to measure cytokine and GRα transcript levels via real-time PCR. The expression levels of GRα and cytokines IL-6, IL-17A and TNF-α did not show significant changes between CS-sensitive and CS-refractory patients on the different days of treatment. However, IL-10 expression levels as the day14-to-day7 ratio were significantly higher in patients sensitive to CS therapy. A higher day14-to-day7 ratio was also found for the IL-6/IL-10, IL-17A/IL-10 and GRα/IL-10 ratios. ROC curve analysis demonstrated a robust predictive performance of IL-10 mRNA expression and the IL-6/IL-10 ratio for identifying CS-refractory patients. In conclusion, the expression of IL-10 and the IL-6/IL-10 ratio hold promise as early predictive biomarkers for CS treatment refractoriness in patients with non-infectious uveitis. These findings offer valuable insights into personalized treatment strategies, potentially leading to improved clinical outcomes. |
| format | Article |
| id | doaj-art-9b2a22e9a422445793b5b21c7980a9bc |
| institution | OA Journals |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-9b2a22e9a422445793b5b21c7980a9bc2025-08-20T02:15:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-05-011610.3389/fimmu.2025.15849051584905IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitisRodrigo A. Valenzuela0Rodrigo A. Valenzuela1Fabian Vega-Tapia2Nathaly Elizalde3Ivan Flores4Felipe M. Rojas5Felipe M. Rojas6Felipe M. Rojas7Felipe M. Rojas8Annelise Goecke9Loreto Cuitino10Loreto Cuitino11Cristhian A. Urzua12Cristhian A. Urzua13Cristhian A. Urzua14Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, ChileLaboratory of Vascular Immunopharmacology, Centro de Biomedicina, Universidad Mayor, Santiago, ChileLaboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, ChileLaboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, ChileLaboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, ChileLaboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, ChileEscuela de Tecnología Médica, Faculta de Medicina, Universidad Andrés Bello, Santiago, ChileServicio de Oftalmología, Hospital Clínico Universidad de Chile, Santiago, ChileDepartamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, ChileRheumatology Section, Medicine Department, Hospital Clínico Universidad de Chile, Santiago, ChileLaboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, ChileServicio de Oftalmología, Hospital Clínico Universidad de Chile, Santiago, ChileLaboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, ChileDepartment of Ophthalmology, University of Chile, Santiago, ChileFaculty of Medicine, Clínica Alemana-Universidad del Desarrollo, Santiago, ChileUveitis, a group of heterogeneous diseases causing ocular inflammation, is a major contributor to vision loss globally. While systemic corticosteroids (CS) are the mainstay treatment, identifying CS-refractory patients remains a significant challenge. This study aimed to explore cytokine expression and Glucocorticoid Receptor (GR) levels as biomarkers for the early detection of CS-refractory cases in non-infectious uveitis. We assayed blood samples from 19 patients with non-infectious uveitis, for the expression of IL-6, IL-17A, TNF-α, IL-10 and GRα. The cohort included 11 refractory and 8 sensitive patients, categorized based on their clinical response to corticosteroids (prednisone 1 mg/kg/day). Blood draws were conducted at three time points (at baseline, day 7- and day 14 after CS initiation), and peripheral blood mononuclear cells (PBMCs) were isolated to measure cytokine and GRα transcript levels via real-time PCR. The expression levels of GRα and cytokines IL-6, IL-17A and TNF-α did not show significant changes between CS-sensitive and CS-refractory patients on the different days of treatment. However, IL-10 expression levels as the day14-to-day7 ratio were significantly higher in patients sensitive to CS therapy. A higher day14-to-day7 ratio was also found for the IL-6/IL-10, IL-17A/IL-10 and GRα/IL-10 ratios. ROC curve analysis demonstrated a robust predictive performance of IL-10 mRNA expression and the IL-6/IL-10 ratio for identifying CS-refractory patients. In conclusion, the expression of IL-10 and the IL-6/IL-10 ratio hold promise as early predictive biomarkers for CS treatment refractoriness in patients with non-infectious uveitis. These findings offer valuable insights into personalized treatment strategies, potentially leading to improved clinical outcomes.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1584905/fullbiomarkerstreatment responsecorticosteroidsrefractorinessinterleukin-10non-infectious uveitis |
| spellingShingle | Rodrigo A. Valenzuela Rodrigo A. Valenzuela Fabian Vega-Tapia Nathaly Elizalde Ivan Flores Felipe M. Rojas Felipe M. Rojas Felipe M. Rojas Felipe M. Rojas Annelise Goecke Loreto Cuitino Loreto Cuitino Cristhian A. Urzua Cristhian A. Urzua Cristhian A. Urzua IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis Frontiers in Immunology biomarkers treatment response corticosteroids refractoriness interleukin-10 non-infectious uveitis |
| title | IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis |
| title_full | IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis |
| title_fullStr | IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis |
| title_full_unstemmed | IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis |
| title_short | IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis |
| title_sort | il 10 and il 6 il 10 as predictive biomarkers for treatment response in non infectious uveitis |
| topic | biomarkers treatment response corticosteroids refractoriness interleukin-10 non-infectious uveitis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1584905/full |
| work_keys_str_mv | AT rodrigoavalenzuela il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT rodrigoavalenzuela il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT fabianvegatapia il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT nathalyelizalde il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT ivanflores il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT felipemrojas il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT felipemrojas il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT felipemrojas il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT felipemrojas il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT annelisegoecke il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT loretocuitino il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT loretocuitino il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT cristhianaurzua il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT cristhianaurzua il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis AT cristhianaurzua il10andil6il10aspredictivebiomarkersfortreatmentresponseinnoninfectiousuveitis |